C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.37 per share when it actually produced a loss of $0.26, delivering a surprise of 29.73%.Over the last four quarters, the company has su ...